Sequenom, Inc., a leading provider of fine mapping genotyping, methylation and gene expression analysis solutions, announced the commercial launch of its MassARRAY TYPER 4.0 genotyping software.
According to a Sequenom press release, TYPER 4.0 significantly enhances data quality, simplifies workflow, and improves ease of use. The software is used in conjunction with Sequenom's iPLEX Gold assay, a multiplexing assay that runs on Sequenom's proprietary MassARRAY System for fine mapping genotyping applications including studies validating the association of single nucleotide polymorphisms (SNPs) with specific diseases.
TYPER 4.0 is designed to provide simple and effective solutions for large size genotyping studies and is expected to further strengthen the Company's leadership position in fine mapping genotyping. The newly launched software includes advanced tools for analyzing, managing, and displaying genotyping data. An improved user interface displays multiple experiments simultaneously to allow easy analysis of data over an entire project. Faster data bank access and new algorithms for automated cluster analysis reduce hands-on time and maximize call rates. Automatic quality control tools also identify discordant genotypes and Mendelian errors, and allow for the development of customized quality control procedures.
"Sequenom now offers what we believe is the industry's best available fine mapping genotyping solution, which is key given the market's rapid expansion as more large scale projects identifying initial associations between SNPs and disease drive follow-on studies to validate those disease associations in large patient populations," said Betty Dragon, Ph.D., Senior Vice President Research & Development. "Our MassARRAY platform and iPLEX Gold assay already provide rapid, high-throughput genotyping in fine mapping studies at the lowest cost per data point for a typical fine mapping study. Now, TYPER 4.0, which was developed through extensive collaboration with our customers, further improves the superior quantitative results uniquely provided by our genotyping assays while also improving overall quality and providing better data management tools through a more customer friendly product."